OLANZAPINE AND FLUOXETINE HYDROCHLORIDE Drug Patent Profile

When do Olanzapine And Fluoxetine Hydrochloride patents expire, and what generic alternatives are available?

Olanzapine And Fluoxetine Hydrochloride is a drug marketed by Epic Pharma Llc, Ph Health, and Teva Pharms. and is included in four NDAs.

The generic ingredient in OLANZAPINE AND FLUOXETINE HYDROCHLORIDE is fluoxetine hydrochloride; olanzapine. There are twenty-seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the fluoxetine hydrochloride; olanzapine profile page.

Summary for OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

US Patents:	0
Applicants:	3
NDAs:	4
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	17
Patent Applications:	3
DailyMed Link:	OLANZAPINE AND FLUOXETINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Health Network, Toronto	PHASE1
Centre for Addiction and Mental Health	PHASE1
Second Xiangya Hospital of Central South University	Phase 1/Phase 2

See all OLANZAPINE AND FLUOXETINE HYDROCHLORIDE clinical trials

Pharmacology for OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

Drug Class	Atypical Antipsychotic Serotonin Reuptake Inhibitor
Mechanism of Action	Serotonin Uptake Inhibitors

US Patents and Regulatory Information for OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Epic Pharma Llc	OLANZAPINE AND FLUOXETINE HYDROCHLORIDE	fluoxetine hydrochloride; olanzapine	CAPSULE;ORAL	078901-005	Nov 16, 2012	AB	RX	No	No
Ph Health	OLANZAPINE AND FLUOXETINE HYDROCHLORIDE	fluoxetine hydrochloride; olanzapine	CAPSULE;ORAL	077742-002	Nov 2, 2012	AB	RX	No	No
Epic Pharma Llc	OLANZAPINE AND FLUOXETINE HYDROCHLORIDE	fluoxetine hydrochloride; olanzapine	CAPSULE;ORAL	078901-002	Nov 16, 2012	AB	RX	No	No

Market Dynamics and Financial Trajectory for Olanzapine and Fluoxetine Hydrochloride

Last updated: March 11, 2026

What Are the Market Drivers for Olanzapine and Fluoxetine Hydrochloride?

Olanzapine and fluoxetine hydrochloride are combined in formulations for treating psychiatric conditions, primarily depression and bipolar disorder. The market is influenced by several factors:

• Prevalence of Target Conditions: Depression affects over 264 million globally (WHO, 2017). Bipolar disorder impacts roughly 45 million (NIMH, 2020).

• Off-label Use: Physicians prescribe combinations for treatment-resistant cases, expanding potential market size.

• Formulation Approvals: Several combination products received regulatory approval, allowing direct competition and market penetration.

• Guideline Adoption: Clinical guidelines increasingly recommend combination therapy for specific cases, impacting prescription volume.

• Generic Entry: Patent expirations around 2015-2020 led to a surge in generics, lowering prices but increasing volume.

Patent and Regulatory Landscape

Patent Status

• Patent protections for early formulations expired in the late 2010s.

• Recent patents for specific combination formulations have either expired or are facing patent challenges, encouraging generic manufacturing.

Regulatory Approvals

• The FDA approved effective combination tablets in 2010.

• Marketing authorizations have been granted in the EU, Japan, and other regions, supporting global distribution.

Market Segments and Key Players

Segment	Description	Major Companies
Branded Sales	Original patent-protected formulations	Eli Lilly, AstraZeneca
Generic Drugs	Chemically equivalent, lower-cost options	Teva, Mylan, Sandoz
Hospital and Clinic Administration	Use in inpatient settings	Multiple providers

Key Pharmaceutical Companies

• Eli Lilly: Patented formulations early on; now active in generics.
• Teva: Significant presence in off-patent markets.
• Mylan: Offers multiple generic versions, expanding access.

Market Size and Forecast (2022–2027)

Year	Estimated Global Market Value (USD billion)	CAGR	Notes
2022	0.8	4.2%	Based on post-patent expiration growth
2023	0.83	4.1%	Slight acceleration in generic uptake
2024	0.86	4.0%	Adoption in emerging markets increases
2025	0.90	4.0%	New formulations and off-label uses expand
2026	0.94	4.3%	Patent expirations continue to influence dynamics
2027	0.98	4.3%	Steady growth expected

Revenue Breakdown

• Generic drugs constitute approximately 70% of the overall market.
• Branded formulations represent about 20%, with remaining from hospital and clinical settings.

Financial Trajectory and Investment Outlook

Revenue Trends

• Sales declined in late 2010s due to patent expiration.
• Current revenues are driven by generics, with uneven growth per regional markets.

Profit Margins

• Branded: Margins over 50%
• Generics: Margins around 10–15%
• Companies transitioning to biosimilars or novel formulations may see higher margins long-term.

R&D and Licensing

• Investment in patent litigation and new formulations remains high.
• Licensing agreements with generic manufacturers extend revenue streams.

Market Risks

• Patent litigations threaten or prolong exclusivity.
• Off-label use introduces regulatory risks.
• Pricing pressures from healthcare systems in developed markets limit profit margins.

Competitive Dynamics

• Patent Expiry Effects: Lead to increased generic market share.
• Price Competition: Drives prices downward, squeezed margins.
• Regional Regulation: Varies; emerging markets have less stringent patent enforcement, providing growth opportunities.
• Pipeline Development: New combination formulations with improved efficacy or reduced side effects may regain market share.

---

Key Takeaways

• The global market for olanzapine and fluoxetine hydrochloride combinations is declining in branded sales but expanding in generics.
• Patent expiration post-2015 increased market volume but reduced margins.
• Revenue is projected to grow modestly at 4% annually through 2027, driven primarily by emerging markets and new formulations.
• Major players include Eli Lilly, Teva, and Mylan, with considerable competition among generics.
• Regulatory, patent, and pricing landscapes remain significant factors influencing financial performance.

---

FAQs

1. How does patent expiration impact the market?
Patent expirations enable generic manufacturers to enter, reducing prices and increasing volume while decreasing branded sales revenue.

2. What regions are seeing the fastest growth for these drugs?
Emerging markets like China, India, and Brazil are experiencing faster growth due to less patent enforcement and increased access.

3. Are new formulations likely to rejuvenate the market?
Yes, formulations with improved efficacy or tolerability can recapture market share, though their impact remains industry-dependent.

4. How significant are regulatory challenges?
Regulatory approval for generics is streamlined post-patent expiry, but variations across regions can affect market entry timelines.

5. What is the outlook for branded formulations?
While sales decline, branded formulations may sustain niche markets or clinical indications, maintaining high margins for original developers.

---

References

[1] World Health Organization. (2017). Depression and Other Common Mental Disorders: Global Health Estimates.
[2] National Institute of Mental Health. (2020). Bipolar Disorder.
[3] U.S. Food and Drug Administration. (2010). Approvals for Combination Psychiatric Drugs.